SIGA Technologies Inc

NASDAQ:SIGA

Earnings Call Analysis

SIGA Technologies Reports Strong 2023 Growth

In 2023, SIGA Technologies experienced significant growth, with product revenues reaching $131 million, marking an impressive 51% increase from the previous year. This surge was the result of diverse sourcing, including a considerable $116 million in sales during Q4 alone, attributed to strategic stockpiles and international contracts. The company's pretax operating income nearly doubled, increasing by 96% to approximately $84 million, reflecting robust earnings capacity. With clinical trials underway to expand TPOXX indications and international sales amounting to $21 million, the company is poised for further expansion. Furthermore, a special dividend payout reflecting a 33% increase signals confidence in SIGA's financial strength and future potential.

Leadership Acknowledgements and Optimistic Outlook

In the fourth quarter and full year of 2023, SIGA Technologies showcased a notable transformation under Phil Gomez's 7-year tenure as CEO, with international expansion and impactful progress for its TPOXX franchise. With Dan Luckshire as CFO and a new CEO at its helm, the company is poised for further growth. The company's future shines bright with firm business fundamentals, proven product franchise in TPOXX, impressive financial performance marked by $75 million in average annual pretax operating income over the last four years, and robust growth opportunities—geographic expansion and new indications for TPOXX.

Financial Highlights and Capital Management Demonstrating Strength

SIGA celebrated historic highs in product revenue at $131 million, indicating a 51% jump from 2022. The strong financials are further evidenced by an impressive 96% growth in pretax operating income to $84 million. They returned value to shareholders through dividends, including a special dividend increase of 33%, underpinning their financial robustness and strategic foresight.

Pipeline Developments and Regulatory Milestones

The company highlighted the progress in expanding TPOXX's indications for post-exposure prophylaxis (PEP) and mpox, with significant safety data supporting the drug's efficacy and lack of serious drug-related adverse events. Alongside, positive results from immunogenicity trials bolstered TPOXX's safety profile. Moreover, SIGA is actively engaged in clinical trials to establish TPOXX's efficacy against mpox worldwide, while it's already approved in Europe and the U.K. for smallpox, mpox, cowpox, and vaccinia complications.

Sales and Commercial Strategy Successes

A diversified customer base contributed to the quarter's success, with significant sales through the U.S. Strategic National Stockpile, Department of Defense, and international contracts, demonstrating global confidence in SIGA’s products. The upcoming fiscal year foresees a positive outlook with a final option exercise for TPOXX by the U.S. Government, valued at $139 million, and an anticipated replenishment cycle of approximately $128 million.

Addressing Manufacturing Bottlenecks and Future Delivery Prospects

SIGA tackled supply chain challenges and manufacturing bottlenecks with strategies aimed at enhancing communications and partnerships. This proactive approach is in place to ensure future product deliveries align with demand and contract fulfillment, showcasing a commitment to operational excellence.

Earnings Call Transcript 2023-Q4

[Operator]

Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties, that could cause actual results to differ from the forward-looking statements.

SIGA does not undertake any obligation to update publicly any forward-looking statements to reflect events or changed circumstances after this call. For a discussion of factors that could cause results to differ, please see the company's filings with the Securities and Exchange Commission, including, without limitation, the company's annual report on Form 10-K, for the year ended December 31, 2023. And its subsequent reports on Form 10-Q and Form 8-K.

I will now hand the call over to Diem Nguyen, CEO of SIGA. Please go ahead.

[Diem Nguyen, executive]

Good afternoon, everyone, and thank you for joining today's call and review of our business results for the fourth quarter and full year of 2023. I am joined by Dan Luckshire, our Chief Financial Officer; and we're pleased to have this opportunity to provide an update to our shareholders. After the update, we'll be happy to answer any other questions.

I'd like to begin by recognizing the work and contributions of Phil Gomez, who served as SIGA's CEO for the 7 years. Phil was instrumental in transforming our company into a more commercial organization, with sales in over 25 countries and securing key regulatory approvals for our TPOXX franchise. On behalf of our team, I want to thank Phil for his many contributions to making SIGA the strong company it is today.

On a personal note, I'm excited to join SIGA and take on the role of CEO. Having spent nearly 3 decades focused on addressing unmet needs in health care, I look forward to building on SIGA's success and driving greater growth for the benefit of our patients, customers and shareholders. I have a deep-seated passion for scientific advancement and innovation, as well as an extensive experience leading successful multibillion-dollar commercial organization. I'm extremely excited to leverage this experience to help fulfill SIGA's potential and have our essential therapies available worldwide.

Although this is only my sixth week with the company, I'm pleased to share my belief in SIGA's bright future. This belief has been grounded for the following: First, SIGA has strong business fundamentals. It is a highly profitable company with a management team that has deep expertise in commercial activities, antiviral R&D and government relations. And the company has built and maintained a fully integrated U.S.-based operational supply chain. This is a distinguishing asset for our customers.

Second, TPOXX is a foundational product franchise that has a track record of securing multiyear government contracts, which have totaled over $1 billion in the past 10 years. Again, this is a point of distinction and speaks to the significant value of TPOXX.

Third, SIGA has achieved best-in-class financial performance. Our average annual pretax operating income over the past 4 years has been $75 million. These results have been achieved, while maintaining a strong balance sheet.

Fourth, SIGA has attractive growth opportunity. Let me just mention a few. In the near term, SIGA has the potential to expand the indications of TPOXX, to include post-exposure prophylaxis, which we like to call PEP and mpox. I'll provide an update on these programs a little later in these remarks.

Also in the near term, SIGA has the opportunity to expand geographically and work with governments across the world, to fully embrace stockpiling and preparedness for a full range of orthopox virus risk. We want to ensure governments have a modernized view of the risk and the tools for protection against orthopox viruses.

And thinking more broadly, SIGA has strong antiviral and government procurement capabilities. We believe these capabilities are best-in-class that we can leverage to move into complementary therapeutic areas with similar points of patient care. Importantly, all of this has reinforced TPOXX' leadership among officious disease common measures. SIGA's expertise and experience in commercial execution, R&D innovation and government contracting enables us to support the highest level of public and individual safety.

As a result of these 4 critical factors, I believe SIGA is well-positioned for further innovation, strong business performance and attractive value creation for our shareholders.

Now turning to our financial results. I am very pleased to report that we finished the year strong. Full year 2023 product revenues of $131 million, are the highest amounts achieved over the past 5 years. This reflects a 51% increase over 2022. Approximately $116 million of the full year product revenues were achieved in the fourth quarter, coming from a diversity of sources including the U.S. Strategic National Stockpile or the SNS, the U.S. Department of Defense and 5 international governments.

Pretax operating income was approximately $84 million in 2023, a 96% increase over 2022. This is a testament to the strength of the SIGA team, the value of our franchise and the resilience of our company. Dan will provide more details on these results shortly. Additionally, in 2023, we spent $43 million on capital management through a combination of special cash dividend and share buyback. And I'm pleased to announce that our Board of Directors has declared a special dividend of $0.60 per share to be paid in April. This represents a 33% increase over the special dividend, we paid in June of 2023.

This demonstrates the financial strength of our company and the confidence the Board and the management team, have in our future. Our proven track record, coupled with the potential of a new long-term contract with SNS provides both a compelling and attractive backdrop for our company in both the short and longer term.

Looking forward, we plan on continuing to invest to grow our business. While maintaining a balanced and disciplined capital allocation approach, with the goal of delivering strong long-term revenues and earnings growth and creating value for our shareholders.

And now I would like to talk about PEP and mpox programs. With regard to PEP, I will start by recapping what was reported on the last investor call. Based on the studies and trials that have been conducted, we believe TPOXX' benefits patients in a prophylactic situation. The FDA has not asked for any additional studies to prove the efficacy of TPOXX for PEP, but has asked for extended safety data in humans for treatment for 28 days. We have completed this requirement and the data is consistent with prior safety studies.

It is important to emphasize the clinical trial results do not show any drug-related serious adverse events. Consistent with TPOXX' existing strong safety profile. In addition to the safety trial, we have completed a Jynneos TPOXX immunogenicity trial, solely to evaluate as TPOXX has an impact on vaccine immune response. Because in the event of an outbreak, TPOXX treatment would likely to be used in combination with a small pox vaccine.

In the preliminary analysis of the data from the immunogenicity trial, consistent with what we expected, the results did not show a meaningful difference between immunogenicity of those who receive the Jynneos vaccine, while on placebo, compared to those that received the Jynneos vaccine, while on TPOXX.

However, as mentioned previously, the results indicated that the number of volunteers who had measurable immune response to the Jynneos vaccine, in both the placebo and TPOXX group was lower than expected. Given these results, the data deemed difficult to assess for the non-inferior statistical determination, which was necessary for the primary endpoint as originally planned in the study.

On the last investor call, we also reported that a subset of the Jynneos and TPOXX samples from the immunogenicity trial were sent to our colleagues at the CDC, who performed their validated print analysis on them. These samples show the expected immune responses. As such, we are now working on getting the entire set of the samples reanalyze, given the challenges associated with the prior analysis conducted by our CRO vendor.

We believe these preliminary CDC analyses provide a potential path forward despite the unexpected nature of the prior results. As such, in parallel, we are working towards a supplemental NDA submission within the next 12 months. We are grateful to our colleagues at the CDC for this collaboration and efficient path forward. We believe this is the best course of action, in terms of getting timely data from the immunogenicity trial, and the FDA agrees as they have been briefed on our plans and have not voiced any objections.

But as a final comment on the PEP program, I want to emphasize that the immunogenicity analysis are not about the efficacy or safety of TPOXX nor are they about TPOXX' impact on those individuals who are showing an immune response. Rather, the relevance of the immunogenicity study is that in the case of an orthopox virus epidemic, be it mpox or smallpox, use of TPOXX with the vaccine for PEP, will be important to reduce the morbidity and mortality of the population without sacrificing patient safety.

Now I would like to shift gears and provide a quick update on the current mpox trials involving TPOXX, which includes 4 randomized controlled trials, as well as multiple observational studies. These studies continue to enroll patients and collect data to provide some specific data points.

In Africa, as of February, NIAID PALM trial being conducted in the DRC, has enrolled approximately 425 patients. A large increase from the 314 patients, noted in our last call. In the NIAID STOMP trial, as of February, there were 267 patients, which is also a substantial increase from the 157 patients noted in our last call. These increases in patient numbers demonstrate that the case counts continue to accumulate especially in Africa.

Importantly, they also provide a glimpse. Some would say a warning into the overall global health risk posed by orthopox viruses. As such, we are working closely with the NIH and other health agencies on randomized clinical trial to demonstrate whether TPOXX is safe and effective for treating mpox in Africa, the U.S. and other parts of the world to achieve the best possible outcome for mpox patients from a public health perspective. I would like to remind, however, TPOXX is approved for smallpox, mpox, cowpox and vaccinia complications in Europe and in the U.K.

At this point, I would like to turn the call over to Dan for the financial update.

[Daniel Luckshire, executive]

Thanks, Diem. As noted earlier in the call, SIGA's strong performance is represented in 2023. Product sales for the 12 months ended December 31, 2023, were $131 million, which is the highest amount achieved over the past 5 years and reflects a 51% increase over 2022.

$116 million of the full year product sales were achieved in the fourth quarter, coming from the diversity of sourcing including the U.S. Strategic National Stockpile, the U.S. Department of Defense and 5 international governments. Fourth quarter product sales include SNS product sales of $98 million, through the delivery of oral TPOXX, $6 million of oral TPOXX sales to the U.S. Department of Defense and $12 million of international sales in oral TPOXX, most of which relate to orders under the HERA contract announced in October of 2023.

I would like to add that the process of product deliveries under existing orders, which started in the fourth quarter of 2023, continued in the first 2 months of 2024, with approximately $15 million of deliveries of oral TPOXX to the SNS and approximately $7 million of international delivery of oral TPOXX.

Pretax operating income, which excludes interest income and taxes was approximately $84 million for 2023. This represents an increase of 96%, over the corresponding 2022 amount. I would like to note that average pretax operating income for the past 4 years, by time period of 2020 to 2023, is $75 million. We believe this average and the 2023 financial results highlight the robust earnings power of SIGA.

Continuing the strong performance, net income for 2023 was $68 million, an increase of approximately 100% from the corresponding amount in 2022. In turn, fully diluted income per share for 2023 is $0.95 versus $0.46 in 2022. At December 31, 2023, the company maintained a strong balance sheet, with a cash balance of approximately $150 million and no debt. In 2023, SIGA spent approximately $43 million of capital management, with a special cash dividend of approximately $32 million and share repurchases of approximately $11 million. Earlier today, the company declared a special cash dividend of $0.60 per share, payable on April 11 for shareholders of record after close of business on March 26.

This concludes the financial update. At this point, I'll turn the call back to Diem.

[Diem Nguyen, executive]

Thank you, Dan. Before I conclude our prepared remarks, I'd like to offer one more insight to my role, as CEO. I am committed to creating shareholder value for our shareholders by doing what I believe is best in the long-term interest of our company, partners and patients. I am bringing a fresh perspective with a sense of urgency to our strategic planning, operational processes, development efforts, and capital allocation just to name a few.

You'll be hearing more from me in the coming months, as our plans evolve and we leverage the progress and momentum from 2023 into 2024. Though in summary, our company is in an exciting and important launch moment as we strategically invest in our research and development programs, expand geographically by broadening our partnerships with governments around the world, leveraged our antiviral experience and expertise to pursue attractive opportunities in other therapeutic areas with similar points to patient care and continue initiatives that directly benefit our shareholders.

Now I would like to open the call to Q&A.

[Operator]

[Operator Instructions] Your first question is from Soo Romanoff from Edison Group.

[Soo Romanoff, analyst]

Congratulations on the quarter, it's nice to see the healthy distribution. My first question was on oral TPOXX delivery. It looks like will mark the last deliveries under the 2018 contract with BARDA, for the oral TPOXX. Have we had any other further discussions with the government, the U.S. Government on possible extensions to the contract or new long-term rolling SNS contracts?

[Diem Nguyen, executive]

Thank you, Soo, for the question. We want to share that we have maintained a continued as well as healthy dialogue with the U.S. Government. At this time, we're targeting an RFP for the SNS, from the Administration of Strategic Preparedness and Response this year. Specifically, we're not in a position to point or pinpoint the exact timing, but we do know that we're prepared to engage in any conversation and address any needs that they may have.

[Soo Romanoff, analyst]

My second question was really on HERA. I mean that was a really big milestone for SIGA. And it was -- have we seen any incremental opportunities developed in the last few months. We saw that nice double-digit million procurement deal that was already signed. What kind of other sales potentials can we assume looking ahead?

[Diem Nguyen, executive]

At this point, as you have all been aware, we have sold to more than 25 countries. There are multiple countries in Europe and beyond, who have ordered in the past who are indicating interest in ordering more TPOXX, often in larger quantity than the prior order. These conversations tend to be productive, but yet iterative. So we will share once we are able to. I will note that we've had $21 million in international sales in 2023, and we are looking to strengthen these sales in the years ahead.

[Operator]

[Operator Instructions] Your next question is from George Will, a Private Investor.

[Unknown Attendee]

I'm not sure if you covered this earlier in the call, but do you -- does SIGA still have an option coming up for later this year, the final option exercise for TPOXX for the U.S. Government?

[Daniel Luckshire, executive]

Yes. This is Dan. And you're correct in that the existing contract does have a remaining option for $113 million for oral TPOXX, as well as an IV TPOXX option for $26 million. I would note that -- I'm sorry, go ahead.

[Unknown Attendee]

That's for the '24 fiscal year?

[Daniel Luckshire, executive]

That's what we're targeting is that those options we are targeting to get exercised this year.

[Operator]

Your next question is from Lance Kimbrough from Ivy Creek Capital.

[Lance Kimbrough, analyst]

Congratulations on the great 2023 results. My question was related to -- in the last quarter call, you had highlighted that there was some manufacturing bottlenecks that we're kind of holding up deliveries it looks like or it sounds like you've worked through those. It was also mentioned that the reorder cycle for 2024 would be approximately $128 million? Do you feel like manufacturing capacity now is such that you can meet that target if it's fulfilled?

[Daniel Luckshire, executive]

Sure. This is Dan. I'll start off and Diem could jump in, if she wants in that. Yes, we did navigate the slow pace of the supply chain towards the end of the year. We are still working on getting that to a more normalized way. We -- I'm not going to say that it's back to where it was a couple of years ago, but we did manage to get deliveries within the fourth quarter for the most part.

Going forward, it will be a continuing focus. Your timing is important in terms of when the order comes in, in terms of when deliveries are made, but provided that we get a timely order from the U.S. Government then we'll be working towards making at least a substantial portion of deliveries this year.

[Diem Nguyen, executive]

Lance, I would just add that given my experiences, running large or commercialized organizations. I recognize the importance of a strong manufacturing capability. So within the weeks that I joined, I started to take a deep dive on the manufacturing partnerships, how we can be more effective in communication. And you will see that we will be working towards successful delivery of products in the future. .

[Lance Kimbrough, analyst]

All right. Well, congratulations again on the great results.

[Diem Nguyen, executive]

Thank you, Lance.

[Operator]

There are no further questions at this time. Please proceed.

[Diem Nguyen, executive]

Well, thank you, Jenny. I just want to pause and say thank you for everyone for their time today and their continued interest in SIGA. As I mentioned in my remarks earlier, SIGA is in an exciting and important launch moment. We look forward to providing you an update with our progress next quarter, and thank you to everyone. Have a great day.

[Operator]

Thank you. Ladies and gentlemen, the conference has now ended. Thank you all for joining. You may all disconnect.